Recombinant Human OPG-Fc Fusion Protein
$200.00 – $900.00
Syd Labs Recombinant Human OPG-Fc Fusion Protein BP000051-GD14, The Osteoprotegerin / OPG / TNFRSF11B / OCIF / OBF activity is calculated by its ability to inhibit TRAIL-mediated cytotoxicity using L929 mouse fibrosarcoma cells treated with TRAIL. The ED50 for this effect is typically 5 ng/mL.
- Product Details
- Description
- Additional information
- More Offers
| Catalog No. | BP000051-GD14 |
|---|---|
| Product Name | Recombinant Human OPG-Fc Fusion Protein |
| Supplier Name | Syd Labs, Inc. |
| Brand Name | Syd Labs |
| Synonyms | Tumor Necrosis Factor Receptor Superfamily Member 11B, TNFRSF11B, Osteoclastogenesis Inhibitory Factor, Osteoprotegerin, OCIF |
| Source | HEK 293-derived. |
| Formulation | In 1% Surcose, 100 mM NaCl, 25 mM L-arginine hydrochloride, and 25 mM sodium phosphate. pH 6.3. |
| Purity | > 90% by SDS-PAGE and RP-HPLC. |
| Endotoxin | < 5.0 EU per 1 ug of the protein by the LAL method. |
| Shipping | The product is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below. |
| Note | Conditions of optimal OPG Protein performance should be determined experimentally by the investigator. |
| Order Offline | Phone: 1-617-401-8149Fax: 1-617-606-5019Email: message@sydlabs.comOr leave a message with a formal purchaseorder (PO) Or credit card. |
Description
BP000051-GD14: Recombinant Human OPG-Fc Fusion Protein
Background
Osteoprotegerin (OPG) also known as Osteoclast Inhibiting Factor (OCIF) or Osteoclast Binding Factor (OBF), is a key factor inhibiting the differentiation and activation of osteoclasts, and is therefore essential for bone resorption. Osteoprotegerin is a glycoprotein belonging to the TNF receptor family. As a so called soluble “decoy” receptor, Osteoprotegerin inhibits the binding of RANK to RANKL and thus inhibits the recruitment, proliferation and activation of osteoclasts.
BP000051-GD14: Recombinant Human OPG-Fc Fusion Protein
Source: HEK 293-derived.
The Osteoprotegerin / OPG / TNFRSF11B / OCIF / OBF activity is calculated by its ability to inhibit TRAIL-mediated cytotoxicity using L929 mouse fibrosarcoma cells treated with TRAIL. The ED50 for this effect is typically 5 ng/ml.
Endotoxin: < 5.0 EU per 1 ug of the protein by the LAL method. Purity: > 90% by SDS-PAGE and RP-HPLC.
Formulation: In 1% Surcose, 100 mM NaCl, 25 mM L-arginine hydrochloride, and 25 mM sodium phosphate. pH 6.3.
Shipping: The product is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution.
Please remember our product information: Recombinant Human OPG-Fc Fusion Protein: BP000051-GD14 Syd Labs
Additional information
| Ship from Country | USA |
|---|---|
| Size | 1 mg, 100 ug |